aod 9604 with retatrutide and retatrutide: evidence, risks, and UK legal status AOD 9604 With Retatrutide: Evidence,

126-129 Gastrointestinal effects of antidiabetic medications Diabetes itself can cause impaired GI function

The phase 2 trial published in The New England Journal of Medicine in 2023 enrolled adults with obesity without type 2 diabetes and demonstrated dose-dependent weight loss of up to 24.2% of body weight at the highest dose over 48 weeks results that attracted considerable scientific and media attention

FAQ Is retatrutide better than Ozempic for weight loss

In June 2026 the MHRA approved the Wegovy pill , the first oral GLP-1 medicine licensed in the UK specifically for weight loss

Retrieved from Goacki, J., Matuszek, M., & Matyjaszek-Matuszek, B

Formulation segments include Injectable, Oral, Nasal, and Transdermal, with Injectables valued at 15.0 to 50.0 USD Billion